John B Liao MD PhD

Gynecologic Oncology

Associate Professor, Obstetrics & Gynecology, University of Washington School of Medicine, Fred Hutchinson Cancer Center

Join to View Full Profile

825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-288-7222
Fax+1 206-598-6963

Education & Training

University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2007 - 2010
Yale UniversityPhD, Investigative Medicine, 2007
Yale School of MedicinePost-Doctoral Fellowship, 2002 - 2004
George Washington UniversityResidency, Obstetrics and Gynecology, 1998 - 2002
George Washington University School of Medicine and Health SciencesClass of 1998, MD
Yale UniversityBA, Molecular Biophysics and Biochemistry, 1994

Certifications & Licensure

WA State Medical License 2010 - 2027
CT State Medical License 2002 - 2010
PA State Medical License 2007 - 2010
VA State Medical License 1998 - 2002
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2017 Mar 14
Completed
Phase 1, Phase 2
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors Start of enrollment: 2017 Dec 14
Terminated
Phase 1, Phase 2
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Completed
Phase 1
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2019 Apr 30
ACTIVE_NOT_RECRUITING
PHASE1
Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian Start of enrollment: 2020 Jun 09
COMPLETED
PHASE2
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2021 Mar 18
ACTIVE_NOT_RECRUITING
PHASE2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors Start of enrollment: 2020 Aug 18
RECRUITING
PHASE2
Oral AMXT 1501 Dicaprate in Combination With IV DFMO Start of enrollment: 2022 Nov 29
TERMINATED
PHASE1, PHASE2
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Start of enrollment: 2023 Nov 15
Not yet recruiting
Phase 2
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer Start of enrollment: 2022 Nov 29
ACTIVE_NOT_RECRUITING
PHASE1
A Study of NX-1607 in Adults With Advanced Malignancies Start of enrollment: 2021 Sep 29
RECRUITING
PHASE1
PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer
RECRUITING
PHASE2
A Study of Sovilnesib in Subjects with Ovarian Cancer Start of enrollment: 2024 Apr 04
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

1 citations
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
John B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, William R Gwin, Jessica L Reichow
Gynecologic Oncology. 2024-12-01
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune respo...
John B Liao, James Y Dai, Jessica L Reichow, Jong-Baeck Lim, Katie M Hitchcock-Bernhardt
Journal for Immunotherapy of Cancer. 2024-11-09
7 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Mary L Disis, Sarah F Adams, Jyoti Bajpai, Marcus O Butler, Tyler Curiel
Journal for Immunotherapy of Cancer. 2023-06-01

Lectures

Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
Weekly Quick Hits (BioHealth Capital Region) – Week of June 5, 2023June 10th, 2023

John B Liao MD PhD

Dr. Liao is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.